Loading...
XNASLSTA
Market cap31mUSD
Jan 10, Last price  
3.73USD
1D
-1.84%
1Q
25.17%
Jan 2017
31.80%
Name

Lisata Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:LSTA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
65.72%
Rev. gr., 5y
25.25%
Revenues
0k
-100.00%
48,56135,26245,724231,66483,54111,565,11869,821,29410,050,08614,329,90014,668,50017,938,79022,487,50035,283,90000000121,372,0000
Net income
-21m
L-61.57%
-1,748,372-1,745,039-6,051,400-10,445,473-9,242,071-25,272,517-23,305,706-47,134,469-53,769,484-38,981,244-54,872,933-80,885,952-32,656,31922,978,700-16,167,000-20,101,000-8,141,000-27,466,000-54,225,000-20,840,000
CFO
-20m
L-5.38%
-1,459,653-833,996-3,638,831-6,132,424-4,732,165-8,648,022-8,476,699-20,927,994-13,852,518-27,101,693-46,895,238-39,258,331-23,667,682-20,875,882-19,986,000-18,882,000-8,823,000-22,245,000-21,170,000-20,032,000
Dividend
Oct 28, 20130.0021 USD/sh
Earnings
Feb 26, 2025

Profile

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
URL
https://www.lisata.com/
IPO date
Nov 03, 1995
Employees
27
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
121,372
 
Cost of revenue
25,897
115,202
Unusual Expense (Income)
NOPBT
(25,897)
6,170
NOPBT Margin
5.08%
Operating Taxes
(2,330)
(2,479)
Tax Rate
NOPAT
(23,567)
8,649
Net income
(20,840)
-61.57%
(54,225)
97.43%
Dividends
Dividend yield
Proceeds from repurchase of equity
321
43
BB yield
-1.46%
-0.33%
Debt
Debt current
168
180
Long-term debt
168
790
Deferred revenue
Other long-term liabilities
210
22
Net debt
(50,199)
(68,256)
Cash flow
Cash from operating activities
(20,032)
(21,170)
CAPEX
(285)
Cash from investing activities
10,102
28,911
Cash from financing activities
385
(224)
FCF
(23,754)
8,415
Balance
Cash
50,535
69,226
Long term investments
Excess cash
50,535
63,157
Stockholders' equity
(528,369)
(507,516)
Invested Capital
576,641
574,347
ROIC
1.54%
ROCE
9.23%
EV
Common stock shares outstanding
8,073
5,180
Price
2.73
7.91%
2.53
200.62%
Market cap
22,039
68.17%
13,105
322.29%
EV
(28,414)
(55,405)
EBITDA
(25,708)
6,239
EV/EBITDA
1.11
Interest
1,949
Interest/NOPBT
31.59%